April 2017- Volume 13, Issue 4
In this Issue
Feature
Show Preview: Immunology 2017--In the interests of immunology
Show Preview: Immunology 2017--In the interests of immunology
The largest annual gathering of immunologists worldwide will hold its annual meeting in Washington, D.C.
Business & Government Policy
On the cutting edge
On the cutting edge
A roundup of instrumentation, software and other tools and technology news
Targets acquired
Targets acquired
A look at a few recent merger and acquisition deals in the pharma world
Just say yes to druggable targets
Just say yes to druggable targets
New biotech Vividion Therapeutics launches with $50-million Series A financing
Contract Services
Strengthening standards for clinical research
Strengthening standards for clinical research
IAOCR seeks to tighten competency requirements, in part with an eye toward life-sciences health of UK post-Brexit
Double the drug discovery options
Double the drug discovery options
Assay.Works and Metrion announce collaboration for expanded service offerings
Genesis Biotechnology acquires PharmOptima
Genesis Biotechnology acquires PharmOptima
Clients will be able to work with one provider for early discovery through preclinical candidate identification
Discovery
Allergens or irritants?
Allergens or irritants?
SenzaGen and AstraZeneca collaborate on respiratory technology development
Santen Inc. tags twoXAR for new deal
Santen Inc. tags twoXAR for new deal
Strategic research collaboration will explore new glaucoma treatments
A pair of GPCR deals for Q1
A pair of GPCR deals for Q1
Heptares inks agreements with Daiichi Sankyo and University of Cambridge centered on GPCRs
A different tack for Alzheimer’s research
A different tack for Alzheimer’s research
‘Jumping genes’ may set stage for brain cell death in Alzheimer’s disease
Preclinical
Making preclinical science stronger
Making preclinical science stronger
Global Biological Standards Institute’s release of reproducibility report adds rigor to research
JAX vs. TNBC
JAX vs. TNBC
Defense Department awards Jackson Laboratory major grants to target triple-negative breast cancer
Valerion reports preclinical potential for Pompe treatment
Valerion reports preclinical potential for Pompe treatment
VAL-1221 could offer more widespread clearance of glycogen than current standard ERT
Attune announces ATN-249 preclinical data
Attune announces ATN-249 preclinical data
Presentation for the oral plasma kallikrein inhibitor for treatment of hereditary angioedema took place at AAAAI 2017
Research & Development
IU applies cell coloring technology to battle superbugs
IU applies cell coloring technology to battle superbugs
Study sheds new light on the biochemical mechanisms behind cellular division in bacteria
Mar matters
Mar matters
Mount Sinai team demonstrates how rare mutations can be lost in stem cell disease modeling of psychosis
A new way to study SVs
A new way to study SVs
Posters at AGBT demonstrate clinical significance of next-generation mapping
‘Eureka moment’
‘Eureka moment’
City of Hope researchers identify possible cause of type 1 diabetes
Diagnostics
Graphene method may lead to low-cost diagnostics
Graphene method may lead to low-cost diagnostics
New approach could enable pinpoint diagnostics on individual blood cells
Positive news for ovarian cancer patients
Positive news for ovarian cancer patients
Peregrine shares data supporting a new kind of cancer diagnostic
New answers in search for diabetic kidney disease diagnostics
New answers in search for diabetic kidney disease diagnostics
Mount Sinai team identifies cellular culprits in disease progression
A clinic-focused agreement
A clinic-focused agreement
NeoGenomics and Definiens link up for clinical trials, clinical testing
Clinical Trials
Blueprint advances on multiple cancer fronts
Blueprint advances on multiple cancer fronts
Encouraging results seen for both BLU-554 and BLU-285, while BLU-667 gains IND approval
Certara launches Simcyp Access
Certara launches Simcyp Access
New licensing approach allows smaller organizations easier access to PBPK modeling and simulation platform
REVEAL-ing the truth about CETP inhibitors?
REVEAL-ing the truth about CETP inhibitors?
International study examines adding anacetrapib to effective LDL-lowering treatment with atorvastatin
Silver lining for selinexor
Silver lining for selinexor
Karyopharm declares Phase 2 SOPRA study of selinexor a failure, but outlook remains bullish
Editor's Focus
That crisp new CRISPR feeling
That crisp new CRISPR feeling
We peek at some relatively recent CRISPR news to whet your appetite as we get ready to devote a special section to the topic in our May 2017 issue
Commentary
Convergence: Where art thou?
Convergence: Where art thou?
There's a lot of talk about the need for convergence in healthcare and life-sciences research, but first we have to cut through a ton of divergent tendencies
Guest Commentary: Using EHR data in research--Pragmatic trials are just the beginning
Guest Commentary: Using EHR data in research--Pragmatic trials are just the beginning
Pragmatic trials could usher in a new era for discovery, but unless we can consistently apply what we know to patients, such discovery will be for naught; as such, we need to tap into the efficiencies of electronic health records and learn to apply these data and IT systems across the entire spectrum of research activities
Q&A
Q&A: How electronic data capture is changing clinical trials
Q&A: How electronic data capture is changing clinical trials
Adam Butler of Bracket touches on the growing adoption of eCOA and RTSM in the clinic
Special Reports
Special Report on Neuroscience: Image-ine that
Special Report on Neuroscience: Image-ine that
Preclinical in-vivo imaging opens new windows on disease
